Anjiolab Completes Phase 2a Clinical Trial for Non-Alcoholic Steatohepatitis Treatment
[Asia Economy Reporter Kwon Jaehee] Anjiolab announced on the 17th that the Phase 2a clinical trial of AL101-NASH, a treatment for non-alcoholic steatohepatitis (NASH), has been completed.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- Seongdong Police Chief Suspected of Commuting with Emergency Vehicle...Inspection to Begin
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "Based on the clinical results, ALS-L1023 is considered a drug that can be safely used in patients with non-alcoholic steatohepatitis," and added, "We plan to present the results of this clinical trial in papers and academic conferences, and also intend to pursue technology transfer."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
